Feedback
Settings

Settings

Goto Application

1. WO2020142612 - PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES.

Submit observation
PermaLink
Publication Number WO/2020/142612
Publication Date 09.07.2020
International Application No. PCT/US2020/012058
International Filing Date 02.01.2020
IPC
C07D 471/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 475/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
475Heterocyclic compounds containing pteridine ring systems
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 475/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
475Heterocyclic compounds containing pteridine ring systems
Applicants
  • GENENTECH, INC. [US]/[US]
Inventors
  • BRAUN, Marie-Gabrielle
  • CASTANEDO, Georgette
  • GIBBONS, Paul
  • RUDOLPH, Joachim
  • VERNIER, William
  • BEVERIDGE, Ramsay
  • WU, Yao
  • WU, Guosheng
Agents
  • SANDERS, Marisa B.
  • SKELTON, Bryan L.
  • CHANG, Cindy
  • SCHILLING, Stephen H.
  • EKENA, Kirk
  • LIEBESCHUETZ, Joe
Priority Data
PCT/CN2019/07027503.01.2019CN
PCT/CN2019/08167308.04.2019CN
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES.
(FR) COMPOSÉS DE PYRIDO-PYRIMIDINONE ET DE PTÉRIDINONE UTILISÉS EN TANT QU'INHIBITEURS DE L'ENZYME NÉCESSITANT L'INOSITOL I (IRE I ALPHA) À ACTIVITÉ ENDORIBONUCLÉASE POUR LE TRAITEMENT DE MALADIES CANCÉREUSES
Abstract
(EN)
Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods treating cancer, alone and in combination with other therapeutic agents.
(FR)
L'invention concerne des composés de pyrido-pyrimidinone et de ptéridinone ou des stéréo-isomères, des tautomères, ou des sels pharmaceutiquement acceptables de ceux-ci, ainsi que les substituants et les caractéristiques structurales décrits ici. L'invention concerne également des compositions pharmaceutiques et des médicaments qui comprennent les composés décrits ici, ainsi que des procédés de traitement du cancer, seuls ou en combinaison avec d'autres agents thérapeutiques.
Latest bibliographic data on file with the International Bureau
# -